Erectile dysfunction answers.

* “yes” in the Bonus column means that you receive 4 Viagra pills X 100 mg FOR FREE.

ED Meds Store has the recreational use of viagra
price for erection trial packs and a very helpful support blog, with the high Technorati authority on tags: viagra , cislis , levitra.

I recieved a message from my good friend:) He said that after trying Viagra+Cialis+Levitra trial pack, he was making love with his wife all the night and next impotence in woman was ready again. I couldn't believe him, In his forty five he has 25 pounds extra weight it was impossible. I've talked to him some more and got the “magic” site url. I've ordered it 3 weeks ago and pills really work! Thank you Mike! (Mike, if you are reading it I think you are smiling:)). I want to share it with all my blog readers. Here is the site where you can get Viagra 10 pills x 100 mg + Cialis 10 pills x 20 mg + Levitra 10 pills x 20 mg softtabs tadalafil
pack for $99.99 only - CLICK HERE and enjoy.

There's also two types of trial erection packs, but I recommend Viagra + Cialis + Levitra pack. If you are sure that one type of tabs works best gfor you - just get it at a quite low prices with guaranteed herbal cure for erectile dysfunction check out all suggestions ED Meds Store and make your choice .

Here are some of the latest health and medical news developments,
compiled by editors of HealthDay:

Impotence Drugs to Carry Hearing Loss
Warnings

New warnings about the potential risk of sudden hearing loss will be
added to the labels of Viagra and other drugs to treat erectile
dysfunction, the U.S. Food and Drug Administration says.

While it's not clear whether the drugs actually do cause hearing loss,
the FDA said that since 1996 there have been 29 reports of hearing
problems among users of these kinds of drugs, the Associated Press
reported.

The new warnings will be carried by the impotence drugs Viagra, Cialis
and Levitra, as well as the pulmonary hypertension drug Revatio, which
contains the same ingredient as Viagra.

In the 29 reports noted by the FDA, hearing loss occurred within hours
to two days after patients took one of the drugs, said FDA ear-and-nose
specialist Dr. Robert Boucher.

“We don't know enough to say that it's ironclad caused by the drugs,
but we see enough to say we can't ignore it either,” he told the
AP.

People who take the drugs and experience hearing loss or ringing in the
ears should stop the medications and contact their doctor, the FDA
said.

—–

San Francisco May Consider Tadalafil prezzo

Site

In what may turn out to be the first step toward opening a
safe-injection site, San Francisco officials co-sponsored a symposium
Thursday on a facility in Vancouver, British Columbia, the only such
program in North America, the Associated Press reported.

At the Vancouver site, about 700 intravenous drug users shoot up
heroin, cocaine and other narcotics under the supervision of nurses. San
Francisco health officials may consider a safe-injection site as a way to
reduce the city's high rate of fatal drug overdoses.

“Having the tadalafil and generic
today will help us figure out whether this is
a way to reduce the harms and improve the health of our community,” said
Grant Colfax, director of HIV prevention for the San Francisco Department
of Health, the AP reported.

However, a federal official said the city's consideration of a
safe-injection site was “disconcerting” and “poor public policy.”

“The underlying philosophy is, 'We accept drug addiction, we accept the
state of affairs as acceptable. This is a form of giving up,” Bertha
Madras, deputy director of demand reduction for the White House Office of
National Drug Control Policy, told the AP.

There are 65 safe-injection sites in 27 cities in eight countries. So
far, San Francisco is the only U.S. city to consider creating a legal
safe-injection site, said Hilary McQuie, Western director for the
nonprofit Harm Reduction Coalition, which promotes alternative drug
treatment methods.

—–

CDC Redesigns Spanish Web Site

The U.S. Centers for Disease Control and Prevention says it's
redesigned its Spanish Web site, CDC en Espanol, with a new look and features meant to
make it more usable and functional.

The redesigned site has a more useful and powerful search engine, quick
access to the 20 most-requested topics of information, a user-friendly A-Z
index, and other features that will make it easier for people to find the
health and science information they seek, the CDC said.

The site, which provides information in Spanish on health issues of
special interest to Hispanic communities, has more than six million
visitors a year and its weekly distribution list includes almost 6,000
members in more than 40 countries.

—–

Sunlight May Decrease Risk of Advanced Breast
Cancer

Exposure to sunlight — which boosts levels of vitamin D in the body –
may reduce the risk of advanced breast cancer, according to a U.S. study
published online this week in the American Journal of
Epidemiology.

The study of 1,788 breast cancer patients and 2,129 women who didn't
have the disease found that women with high sun exposure had half the risk
of developing advanced breast cancer than women with low sun exposure.
However, this effect was noted only in women with naturally light skin
color.

“We believe that sunlight helps to reduce women's risk of breast cancer
because the body manufactures the active form of vitamin D from exposure
to sunlight,” lead researcher Esther John, of the Northern California
Cancer Center, said in a statement. “It is possible that these effects
were observed only among cialis wonder buy genuine tadalafil
women because sun exposure produces
less vitamin D among women with naturally darker pigmentation.”

John and her colleagues emphasized that women should not sunbathe in an
attempt to reduce their breast cancer risk.

“If future studies continue to show reductions in breast cancer risk
associated with sun exposure, increasing vitamin D intake from diet and
supplements may be the safest solution to achieve adequate levels of
vitamin D,” co-researcher Gary Schwartz, of the Comprehensive Cancer
Center at Wake Forest University School of Medicine, said in a
statement.

—–

Bad Habits Increase Osteoporosis
Risk

Smoking, excess alcohol consumption, being underweight, lack of
exercise, and poor nutrition are factors that could increase the risk of
osteoporosis later in life, says an International Osteoporosis Foundation
(IOF) report released to mark World Osteoporosis Day on Oct. 20.

Osteoporosis risk factors fall into two main categories, modifiable and
fixed. People can't control fixed risk factors — such as age, gender, and
family history — but they can do things that may lessen their
effects.

Following a bone-healthy lifestyle — including eating a nutritious
diet, getting regular exercise, and avoiding smoking and excess alcohol
consumption — can help build strong bones and prevent fractures, the IOF
said.

By 2050, it's estimated that the incidence of hip fracture (a major
consequence of osteoporosis) will increase by 310 percent in men and 240
percent in women, according to IOF Chief Executive Officer Daniel
Navid.

Report author and IOF board member Professor Cyrus Cooper said if
“people recognize osteoporosis risk factors when they are young and take
appropriate action, it can have enormous positive impact on their bone
health in later years.”

—–

Millions of American Teens Smoke, Drink, Use
Drugs Each Day: Report

On an average day in 2006, 1.2 million American teens smoked
cigarettes, 631,000 drank, 586,000 used marijuana, almost 50,000 used
inhalants, 27,000 used hallucinogens, 13,000 used cocaine, and 3,800 used
heroin, according to a government report released Thursday.

It also found that on an average day, almost 8,000 adolescents ages 12
to 17 drank alcohol for the first time, about 4,300 used an illicit drug
for the first time, about 4,000 smoked cigarettes for the first time,
almost 3,600 used marijuana for the first time, and about 2,500 abused
pain reliever for the first time.

The report, by the U.S. Substance Abuse and Mental Health Services
Administration (SAMHSA), is based on national surveys conducted and
analyzed by the agency's Office of Applied Studies.

“While other studies have shown that significant progress has been made
in lowering the levels of substance abuse among young people in the last
few years, this report shows many young people are still engaging in risky
behavior,” SAMHSA Administrator Terry Cline said in a prepared
statement.

“By breaking the data down and analyzing on a day-to-day basis, we gain
fresh perspective on how deeply substance abuse pervades the lives of many
young people and their families,” Cline said.

To: MEDICAL EDITORS

Contact: John Murphy, +1-507-284-5005 (days), +1-507-284-2511 (evenings), e-mail: newsbureau@mayo.edu

ROCHESTER, Minn., Oct. 4 /PRNewswire-USNewswire/ — Although medication
can help extend the lives of men with chronic heart failure, several factors
associated with this disease can interfere with a person’s ability to engage
in and enjoy sexual activities. Fatigue, depression, medication side effects
and the fear of damaging the heart can cause people with chronic heart failure
to lose interest in sex or wonder whether this activity is safe for them.

A literature review published in the October issue of Mayo Clinic
Proceedings finds that with proper screening and treatment, many patients with
chronic heart failure can safely engage in sexual activity.

Methods

Co-authors Stacy Mandras, M.D., Patricia Uber, Pharm. D., and Mandeep
Mehra, M.D., conducted systematic independent literature searches using the
MEDLINE database and examined a broad range of medical research that focused
on chronic heart failure, sexual activity and sexual dysfunction. This
literature included data from patient surveys and clinical trials.

Findings

Many people with chronic heart failure worry that having sex will place
too great a strain on the heart. To address this issue, Drs. Mandras and Mehra
analyzed studies that showed the impact of sexual activity on heart rate,
blood pressure and respiratory rates, which typically increase during sexual
activity and other forms of exertion.

One study the authors reviewed measured these changes in middle-aged men
with and without coronary artery disease. This study found that the peak heart
rate during intercourse was lower than heart rates measured during the
patients’ normal daily activities. The study participants’ peak oxygen
consumption levels during intercourse were moderate — comparable to their
oxygen consumption levels during moderate activities such as walking on level
ground at 3 to 4 miles per hour, climbing stairs slowly or doing general
housework such as vacuuming.

The authors also addressed how to counsel and treat chronic heart failure
patients who are coping with erectile dysfunction, difficulty achieving or
maintaining an erection. Researchers estimate that erectile dysfunction
affects 60 percent to 70 percent of people who have chronic heart failure.

The authors observe that multiple factors may be involved. In addition to
decreased exercise capacity, patients with chronic heart failure have blood
vessel and circulation abnormalities that can reduce blood flow into the penis
and interfere with the ability to maintain an erection. And erectile
dysfunction can be caused or worsened by many of the medications that are
commonly prescribed to treat chronic heart failure.

Currently, the preferred treatment for erectile dysfunction includes
sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis). However,
numerous experts have raised concerns about the use of these drugs in patients
with chronic heart failure who also take nitrates (or other medications that
relax and widen blood vessels). This drug combination has been shown to be

dangerous, because it can increase the risk for a life-threatening drop in
blood pressure.

To further explore this potential risk, the authors reviewed results from
a variety of studies in which male patients with congestive heart failure took
sildenafil. The authors observed that more data are needed to determine the
safety of the newer drugs, vardenafil and tadalafil, for these patients.

“Taken together, these studies show that erectile dysfunction in patients
with mild to moderate chronic heart failure can be safely and effectively
treated with sildenafil, provided that patients are tadalafil pill
ly screened
before therapy,” say the authors.

For those patients who cannot take erectile dysfunction medications, the
authors counsel that an exercise training regimen may be an appropriate
substitute therapy to enhance sexual function and quality of life. The authors
stress that clinicians should focus on the sexual activity history of chronic
heart failure patients and not ignore it, since addressing this element can
substantially improve their quality of life.

Background about chronic heart failure

Chronic heart failure often develops after other cardiac problems have
damaged or weakened the heart, leaving it too weak or too stiff to fill and
pump efficiently. Many underlying heart conditions can lead to heart failure.
It can develop quickly after damage caused by a heart attack, or it can
develop gradually after years of high blood pressure or coronary artery
disease.

A peer-review journal, Mayo Clinic Proceedings publishes original
articles, reviews and editorials dealing with clinical and laboratory
medicine, clinical research, basic science research and clinical tadalafil soft tablet
.
Mayo Clinic Proceedings is published monthly by Mayo Foundation for Medical
Education and Research as part of its commitment to the medical education of
physicians. The journal has been published for more than 80 years and has a
circulation of 130,000 nationally and treat erectile dysfunction the best. Articles are available
online at http://www.tadalafil 20mg
.com.

To obtain the latest news releases from Mayo Clinic, go to
http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is
available as a resource for your health stories.

SOURCE Mayo Clinic

-0-

NEW YORK (Reuters) -
Eli Lilly and Co. (LLY.N) on Tuesday
posted compare viagra to cialis
quarterly earnings and raised its
2007 forecast, helped by surging sales of its prescription
drugs, including depression treatment Cymbalta.

Lilly posted strong revenue gains from Cymbalta and Zyprexa
for schizophrenia, which rose 67 percent and 9 percent,
respectively, and helped the company beat revenue expectations
by about $250 million.

“Together these two products accounted for almost two
thirds of the revenue beat,” JPMorgan analyst Roberto Cuca
wrote in a research note. “This should boost sentiment among
those investors who had been concerned about the health of
Lilly's (central nervous system) franchise.”

The second-quarter results also signaled Lilly's
acquisition of Icos in January is paying off, accounting for
about a third of the 20 percent jump in quarterly sales to
$4.63 billion. Through that deal, Lilly gained full ownership
of the widely used Cialis impotence pill, which posted a 26
percent rise in sales to $293 billion.

Lilly shares rose 2 percent in opening trade.

Excluding charges related to tadalafil rezeptfrei
of Hypnion Inc.
and Ivy Animal Health in the period, Lilly earned 90 cents per
share, which was 8 cents better than analysts had expected,
according to Reuters Estimates.

On a net basis after those charges, the Indianapolis-based
drug maker earned $664 million, or 61 cents per share, from
$822 million, or 76 cents per share, a year earlier.

Lilly forecast 2007 earnings per share, excluding special
items, of $3.40 to $3.50 per share, up from its previous
forecast of $3.29 to $3.39 per share. It expects sales to grow
in the “mid-teens” percentage range.

Cymbalta's revenue rise to $520 million in the second
quarter was helped by its new use against generalized anxiety
disorder approved by U.S. regulators in February.

Meanwhile Zyprexa, the company's biggest product, rebounded
with a 9 percent rise to $1.21 billion after earlier sales
declines prompted by concerns over its tendency to cause weight
gains.

Lilly said higher overseas sales of Zyprexa, along with
higher U.S. prices, outstripped lower U.S. demand for the
medicine. The company projected “modest” worldwide sales growth
of Zyprexa for the full year.

Gemzar, used to treat lung and pancreatic cancer, grew 15
percent to $396 million, while lung cancer treatment Alimta
jumped 35 percent to $207 million.

Sales of Strattera, used to treat attention deficit
hyperactivity disorder, slipped one percent to $142 million,
amid concerns that such drugs pose heart risks and cause
psychiatric problems, such as liquid tadalafil
.

Eli Lilly shares rose $1.12 to $58.29 in opening trade on
the New York Stock Exchange. They are up 12 percent in 2007,
outpacing a 2 percent rise for the American Stock Exchange
Pharmaceutical index. (.DRG)

(Reporting by Ransdell Pierson and Lewis Krauskopf)